

development pipeline

For more than 28 years, Genentech has excelled at transforming scientific discoveries into breakthrough therapies for patients. Since the start, we have directed our drug discovery efforts towards therapies that would fill unmet medical needs. Today, Genentech's development pipeline focuses on oncology, immunology, vascular medicine and

specialty therapeutics. The pipeline has both breadth and depth, with more than 20 projects targeting a range of disease areas across all phases of clinical development. The pipeline below is current as of March 12, 2004, and reflects several updates to our 2003 Form 10-K.

Pre-IND / Phase 1		
Oncology	G-024856 PRO1762 (Apo2L/TRAIL)	Basal Cell Carcinoma* Cancer Therapy*
Immunology	PRO70769 (Anti-CD20)	Rheumatoid Arthritis
Vascular	PRO128115 (VEGF)	Wound Healing
Phase 2		
Oncology	Omnitarg™	Breast Cancer Lung Cancer Ovarian Cancer Prostate Cancer
Immunology	Tarceva™	Glioblastoma Multiforme
	RAPTIVA™	Psoriatic Arthritis
	Rituxan®	Mod.-to-Sev. Rheumatoid Arthritis Multiple Sclerosis*
	Xolair®	Peanut Allergy*
Phase 3		
Oncology	Avastin™	Adjuvant Colorectal Cancer* Metastatic Breast Cancer Non-Small Cell Lung Cancer Pancreatic Cancer* Renal Cell Carcinoma
Immunology	Herceptin®	Adjuvant Breast Cancer
	Rituxan®	Aggressive Frontline Non-Hodgkin's Lymphoma Indolent Frontline Non-Hodgkin's Lymphoma** Indolent Maintenance Non-Hodgkin's Lymphoma Relapsed Chronic Lymphocytic Leukemia
	Tarceva™	Refractory Lung Cancer Pancreatic Cancer
	Rituxan®	ANCA-Associated Vasculitis* Lupus Nephritis* Refractory Rheumatoid Arthritis Systemic Lupus Erythematosus*
Vascular	Xolair®	Pediatric Asthma*
	Lucentis™	Age-Related Macular Degeneration
	Veletri™	Acute Heart Failure
Specialty	Nutropin Depot®	Adult Growth Hormone Deficiency**

Filed sNDA		
Specialty	Nutropin® & Nutropin AQ®	Idiopathic Short Stature

*Preparing for Phase
**Preparing for Filing